CYXO — Cyxone AB Share News
0.000.00%
Last trade - 00:00- SEK14.25m
- SEK8.44m
Brief: Cyxone Q4 Pre-Tax Loss At SEK 9.9 Million
Brief: Cyxone Orders More Rabeximod Substance And Confirms Timeline For The Phase Iib Program
Brief: Cyxone Orders More Rabeximod Substance And Confirms Timeline For Phase IIb
Brief: Cyxone Assigns Aptuit For The Capsulation Of Phase II Candidate Rabeximod
Brief: Cyxone Signs UK Contract Research Organization For Six-Month Toxicology Studies With Rabeximod
Brief: Cyxone Q3 Pre-Tax Loss Widens To SEK 5.8 Million
Brief: Cyxone Says Kjell G. Stenberg Steps Down As CEO
Brief: Cyxone Explores Orphan Drug Designation For Rabeximod
Brief: Cyxone Q2 Loss After Financial Items Widens To SEK 4.4 Mln
Brief: Cyxone: Study Confirms Drug Candidate T20K's Safety And Tolerability In Humans
Brief: Cyxone Submits Application To Start First-In-Human Trial With T20k In MS
Brief: Cyxone Forms A Subsidiary In Switzerland
Brief: Cyxone Q1 Pre-Tax Loss Widens To SEK 4.8 Million
Brief: Cyxone Announces Strategic Intent To Position Its Drug Candidate T20K In MS As Prophylactic Agent
Brief: Cyxone Q4 Pre-Tax Loss Widens To SEK 4.5 Million
Brief: Cyxone Comments On Decision From The Disciplinary Committee
Brief: Cyxone: Issuance Of US Divisional Patent For Drug Candidate T20K In MS
Brief: Cyxone Q3 Pre-Tax Loss Widens To SEK 4.4 Mln
Brief: Cyxone AB Gets About Sek 44.3 Million In Rights Issue